Detalhe da pesquisa
1.
No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.
Pharmacogenet Genomics
; 15(10): 713-21, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16141797